Precision fermentation in an ingredient development context is defined as the use of genetically engineered microbes to make a specific molecule, rather than relying on the microbe as the final ingredient or on a traditional fermented food matrix. In bread, beer and yoghurt, the organism and its metabolism are part of the product identity. Precision fermentation is more directed because the target molecule, not the whole fermented matrix, is the product.
A microorganism, commonly E. coli, yeast or a filamentous fungus, is given biosynthetic instructions, meaning selected DNA sequences that encode the enzymes needed to make a target compound. That cell then grows in a bioreactor, a controlled vessel for microbial cultivation, where temperature, pH, oxygen and nutrients are organised to support both growth and product formation. The molecule is harvested from the fermentation broth, the liquid culture medium, and is then extracted and purified. The production strain is removed and its absence is verified.
The ingredient developer is no longer constrained by the biology, seasonality or scalability of the original source. What is interesting is that this makes synthetic biology ingredient production feel less like farming and more like controlled manufacturing, although biology still sets the rules. MarketsandMarkets estimates the precision fermentation ingredients market to grow from USD 5.02 billion in 2025 to USD 36.31 billion by 2030, at a CAGR of 48.6 percent, reflecting both scale up potential and pressure for more resilient, sustainable supply chains1.
So what does this actually look like in practice? At a high level, precision fermentation takes a defined molecular target and builds a microbial production route around it. Here is how it breaks down.
First, the molecule that needs to be produced is defined. That may be a protein, glycan, enzyme, vitamin, flavour compound or another functional ingredient. This choice determines the biosynthetic pathway, meaning the set of enzyme-driven reactions required to make the molecule inside the host organism. In practical terms, the target defines the biological blueprint.
The next step is to programme the production strain. Common hosts include E. coli, yeasts and filamentous fungi, selected for growth behaviour, genetic tractability and industrial robustness. Genes are introduced that code for the enzymes the host does not naturally make, using modern molecular biology tools that allow us to introduce completely new metabolic pathways into the host’s DNA. Next the flux through pathways that supply the required donor substrates is further optimized, and any enzymes that act in competing routes are tuned down. The concept is simple: push more of the cell’s carbon towards the target molecule of interest. For HMOs, this means adding glycosyltransferase genes and pathways that supply the activated sugar donors, and blocking lactose breakdown so that it remains available as the acceptor substrate.
The engineered microbe is grown in a bioreactor under carefully optimised conditions. Common feedstocks are used as carbon source, and various parameters such as temperature, pH, dissolved oxygen and feeding strategy all affect yield, productivity and impurity profile. For HMOs, fed-batch fermentation is widely used, where the nutrients are added over time rather than all at once. Fermentation duration and volumetric productivity (i.e. the amount of product generated per litre per hour) are key economic drivers, and optimising both is central to making HMO production commercially viable at scale.
Following fermentation, the target molecule is separated from the fermentation broth and converted into an ingredient. Downstream processing typically begins with filtration to fully remove the production organism and clarify the broth, followed by further purification steps which, depending on the molecule and application, may include additional filtration, chromatography, concentration and crystallisation or spray drying. This results in a stable, free-flowing powder. Each batch undergoes rigorous analytical testing to confirm identity, purity, and safety before release. What remains is a purified, high-quality ingredient ready for formulation.
Process flow diagram description for designer: Target → Engineer → Ferment → Purify → Ingredient
This is the working definition of precision fermentation in action: synthetic biology ingredient production organised as a repeatable manufacturing process.
So how do precision and traditional fermentation compare? Traditional fermentation usually values the living culture, its metabolic activity, and the transformed food matrix, while precision fermentation is designed to recover a specific molecule made by that culture. Different objective. Different process logic.
In traditional fermentation, as with beer, yoghurt or kombucha, the microbial culture is part of the product identity. The organism converts sugars and other substrates into acids, alcohols, gases and flavour compounds. Often, that complexity is exactly the point. Genetic engineering, meaning deliberate modification of DNA, is absent or limited.
Precision fermentation is more controlled. The microbe is engineered to produce a target molecule, then the molecule is extracted and purified. The microbe itself is removed. The key distinction is not that one method is inherently more robust than the other, but that they are designed for different outcomes: traditional fermentation typically produces a transformed food, beverage or culture, whereas precision fermentation produces a defined molecule that is subsequently isolated and purified.
|
Traditional fermentation |
Precision fermentation |
|
Fermented food is the product; the culture shapes its identity (e.g. beer, yoghurt and kombucha). |
A specific target molecule is produced by the microbe. The microbe is not in the final product |
|
No or minimal genetic engineering of the microbe |
Core to the process. Engineered biosynthetic pathways for the target molecule |
|
Process performance depends on the natural characteristics of the microorganism and the requirements of the fermented product. |
Process performance can be optimised through strain engineering, fermentation conditions and downstream processing. |
|
Products: fermented foods and beverages |
Products: proteins, glycans, enzymes, vitamins, pigments and flavours |
So what can this technology actually produce? Quite a lot, although the answer depends on whether the target molecule is a protein, glycan, small molecule or enzyme. Precision fermentation ingredients are best understood as purified molecules made by microbes, rather than as fermented foods.
Dairy proteins: Dairy proteins are the most visible example. Whey proteins, especially beta-lactoglobulin, and caseins can be produced by engineered microbes, with companies such as Perfect Day and Remilk helping to define the category. Regulatory progress is molecule and jurisdiction specific: Perfect Day received a US FDA no questions letter for beta-lactoglobulin produced by Trichoderma reesei, Remilk has notified beta lactoglobulin produced by Komagataella phaffii as GRAS, while in the EU, no precision-fermented dairy protein has yet been authorised as a novel food at the time of writing.
Enzymes: Enzymes are the older story. Chymosin, the milk-clotting enzyme used in cheesemaking, is often considered as the original precision fermentation ingredient; fermentation derived chymosin entered commercial use in the early 1990s and became a practical replacement for calf rennet.
Vitamins: Vitamins sit in a related category. Riboflavin, vitamin B2, is now largely made by industrial fermentation using overproducing microbial strains, while vitamin B12 is exclusively produced by microbial fermentation.
Flavours, sweeteners and pigments: Flavours and pigments are another important group: vanillin, saffron associated apocarotenoids, steviol glycosides and related sweet taste molecules all illustrate how synthetic biology can redirect microbial metabolism towards high value compounds.
Human milk oligosaccharides: HMOs, produced by companies such as Inbiose, are a clear example of modern precision fermentation: producing structurally complex glycans that are otherwise difficult to source or synthesise at scale. 2’FL, 3FL, LNnT, LNT, 3’SL and 6’SL are now produced commercially through fermentation routes, making HMOs one of the clearest examples of ingredient production by synthetic biology moving into mainstream nutrition. For a deeper technical view, see our dedicated guide on precision fermentation for HMOs.
EU: Novel Food Regulation (EU) 2015/2283
For ingredient developers, the first question is usually market access. In the EU, precision fermentation ingredients that were not consumed to a significant degree before 15 May 1997 typically fall under Novel Food Regulation (EU) 2015/2283. It is important to note that authorisation is required before market placement. The dossier covers identity, composition, production process, safety evidence and proposed conditions of use. Several HMOs, including 2’FL, 3FL, LNnT, LNT, 3’SL and 6’SL, have been authorised as novel foods, although dossier specifics vary by structure, production strain and applicant2.
US: FDA GRAS pathway
In the US, the typical route is GRAS, Generally Recognized As Safe3. A company may submit a GRAS notice to the FDA, which reviews the basis for the safety conclusion and may issue a no questions letter. Several HMO structures have GRAS notices from multiple suppliers. Each notice covers the notifier’s own substance, specification and production process, so one supplier’s notice does not automatically cover another supplier’s material.
Does precision fermentation imply a GMO label?
Precision fermentation usually involves a genetically modified production organism. The microbe is engineered so it can produce the target molecule, but it is also removed during downstream processing. Regulatory classification depends on jurisdiction, production process and product category. In Europe, a food produced with a genetically modified microorganism, rather than from it, generally falls outside the GM food and feed legislation, provided that the absence of viable cells and recombinant DNA is demonstrated4. Novel Food assessment may also apply where the ingredient is novel, even if the final ingredient contains no viable production organism.
For ingredient developers, precision fermentation changes the development story. Instead of sourcing a scarce or variable biological material, manufacturers are offered a more stable manufacturing route for a defined molecule.
Supply security is the first advantage. Biological production routes can reduce dependence on agricultural harvests, animal-derived inputs, seasonal variation and geographic sourcing constraints. For teams managing ingredient risk, that matters.
Then there is structural precision. Enzymes in the production strain build each linkage with the correct position and orientation in a single biological process, which chemical synthesis can only achieve through multiple protection and deprotection steps. For bioactive ingredients such as HMOs, where structure strongly influences biological function, that precision is not a detail. It is the product. See our deeper note on precision fermentation for HMOs and our complete HMO guide.
The scalability of precision fermentation is also different from many extraction or chemical synthesis routes. Once the strain, medium and process are established, the same biological logic can move from laboratory scale to industrial vessels, although scale-up still requires careful validation. Fermentation-based ingredient production is iterative; better strains, better feeding strategies and improved recovery steps steadily improve yield.
Sustainability is part of the same conversation. Many precision fermentation ingredients can be made with lower land, water and chemical inputs than extraction-based alternatives. Costs are moving too. HMO production costs have decreased over the past decade, largely because strain productivity and downstream processing have improved together with an increased production scale.
If you are evaluating a route from lab-scale proof of concept to commercial production of any bio-active carbohydrate, including HMOs, Inbiose can help you assess the technical, development and regulatory path.
Discuss your precision fermentation project with our team.
In short, traditional fermentation usually produces a food or beverage through the activity of natural microbes, as in yoghurt, beer or kombucha. Precision fermentation is different because the microbe is genetically engineered to produce a specific target molecule, which is then harvested and purified.
Not in the usual sense. The production organism is typically genetically modified, but the final ingredient is a purified molecule that contains no viable GM organism.
Precision fermentation ingredients already include enzymes, dairy proteins, vitamins, flavours, pigments and glycans, carbohydrate structures with biological function. Chymosin, used in cheesemaking, is the classic early example. More recent examples include beta lactoglobulin, caseins, vanillin, steviol glycosides and human milk oligosaccharides.
In the EU, fermentation-derived ingredients not consumed to a significant degree before 15 May 1997 generally fall under Novel Food Regulation (EU) 2015/2283. Enzymes, additives and flavourings follow separate rules. After EFSA assesses the safety dossier, the European Commission authorises the ingredient by adding it to the Union list. An authorisation is generally open to all companies, unless it comes with five years of data protection based on proprietary scientific data.
Common production hosts include bacteria such as E. coli, yeasts (Saccharomyces cerevisiae or Komagataella phaffii), and filamentous fungi such as Trichoderma reesei. The host is chosen for growth behaviour, genetic tractability, productivity, safety history and target molecule of interest. There is no single best organism in industrial technology.
The development process typically starts by engineering a microbial host to build a defined human milk oligosaccharide (HMO). The production organism is then cultivated under tightly controlled conditions in a bioreactor using widely available feedstock sugar and lactose as the raw material inputs. During the fermentation, the target HMO accumulates, after which it is isolated from the broth during the downstream purification process.
Cost depends on titre, yield, productivity and downstream recovery. Titre means the product concentration in the fermentation broth, yield describes how efficiently feedstock becomes product and productivity is the amount of product formed per litre of broth per hour. Early precision fermentation ingredients can be expensive, especially when purification is complex. The pattern, however, is encouraging. As strain engineering improves and industrial volumes increase, costs tend to fall. HMO production is a good example of that trajectory.
Precision fermentation is highly scalability because the same biological production logic can often move from laboratory vessels to industrial bioreactors. Chemical synthesis may be excellent for simple molecules, but complex stereospecific structures can require many steps and repeated process validation, which is often hard to scale economically. With the right production infrastructure at hand, precision fermentation is generally more economical to scale for complex glycans compared to multistep chemical synthesis.
While Inbiose strives to ensure the accuracy and timeliness of the information presented in this document, the company makes no guarantees or assurances regarding the precision, reliability, or completeness of the content. This information is intended solely for scientific and technical purposes in business-to-business communications. Local regulations and requirements should be reviewed when considering product labeling or advertising to end consumers. The information provided does not constitute medical or scientific advice, diagnosis, or treatment, and is offered without any warranties, express or implied. Inbiose shall not be held liable for any damages resulting from the use or interpretation of the material presented herein. The reader assumes full responsibility for their use of the information. No liability is accepted for any infringement of patents resulting from the use of the information provided. Content may be updated without prior notice. For further information, please contact your local Inbiose representative. All trademarks mentioned are owned by or licensed to Inbiose unless otherwise noted.
